Passage Bio (PASG) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio (PASG) has outperformed TScan Therapeutics (TCRX) over the past year, losing 54.3% versus a loss of 88.5%. Over five years, TCRX leads with a -96.6% price change compared with -98.1% for PASG. TScan Therapeutics is the larger company by market cap ($15.5 million vs $12.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PASG | TCRX |
|---|---|---|
| Share price | $3.78 | $0.2282 |
| Market cap | $12.16M | $15.47M |
| 1-day change | -1.95% | -17.59% |
| YTD return | -67.97% | -77.18% |
| 1-year return | -54.35% | -88.47% |
| 5-year return | -98.06% | -96.62% |
| EPS (TTM) | $-11.33 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.00 | $2.57 |
| 52-week low | $3.29 | $0.224 |
| Distance from 52-week high | -81.10% | -91.12% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +310.05% | +338.21% |
| Average volume | 26.11K | 783.59K |
| Shares outstanding | 3.22M | 63.50M |
| Employees | 24 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed TCRX by 34.1 percentage points over the past year.
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
PASG vs TCRX FAQ
Which is bigger, Passage Bio or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $15.47M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, PASG or TCRX?
PASG returned -54.35% over the past 12 months, compared with -88.47% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Passage Bio and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.